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Angiotensin receptor blockers and antiplatelet
agents are associated with improved primary
patency after arteriovenous hemodialysis
access placement
Rubie Sue Jackson, MD, MPH,a,b Anton N. Sidawy, MD, MPH,a,c Richard L. Amdur, PhD,a,b
Akhil Khetarpal, MS,a and Robyn A. Macsata, MD,a,b Washington, DC
Objective:Dialysis access failure is a major cause of morbidity, mortality, and cost in end-stage renal disease. We undertook
a study to determine the influence of medication use on dialysis access failure.
Methods: After institutional review board approval, we performed a retrospective analysis of all upper extremity
hemodialysis accesses placed from 2005 to 2009 at the Washington DC Veterans Affairs Medical Center. For each access,
the date of failure was recorded. For patients who died or were lost to follow-up, the date of the last documented
functional patency (censoring) was recorded. The primary exposures were 12 medication classes. Patient demographics,
behaviors, comorbidities, and access characteristics were used as covariates. Patency rates were calculated using
Kaplan-Meier methods. Cox proportional hazard models controlling for patient characteristics and all medication classes,
with procedures clustered within patients, were used to determine the influence of medication class on primary patency.
Results: Two hundred sixty autogenous and 126 prosthetic newly placed accesses were identified. Of these, three lower
extremity accesses and six accesses with unknown thrombosis date were excluded. Forty-five (18%) of the remaining 257
autogenous accesses were excluded for primary nonfunctionality (patent, but with inadequate venous dilatation for
initial hemodialysis), because the primary outcome was long-term functional patency. The remaining 212 autoge-
nous and 120 prosthetic accesses were analyzed. Primary patency rates at 1 and 2 years were 55.2% and 49.1% for
autogenous accesses, and 50.2% and 29.7% for prosthetic accesses, respectively. On multivariable analysis, angio-
tensin receptor blockers (ARBs) were associated with reduced hazard of both autogenous (hazard ratio [HR], 0.35;
95% confidence interval [CI], 0.16-0.76; P  .008) and prosthetic (HR, 0.41; 95% CI, 0.18-0.95;P  .039) access
failure. On subgroup analysis, ARBs prolonged autogenous access primary patency among patients receiving
antiplatelet medication (aspirin, clopidogrel; HR, 0.16; 95% CI, 0.05-0.52;P  .002) but had no demonstrable
benefit among patients not receiving antiplatelets (HR, 1.35; 95% CI, 0.34-5.31;P  .670). There were no
significant drug–drug interactions in the analysis of prosthetic accesses. Weighted regression models demonstrated
low multicollinearity among the model variables.
Conclusion: Our data suggest that therapy with an ARB plus antiplatelet agent is associated with prolonged autogenous
access primary patency, and therapy with an ARB with or without antiplatelet agents is associated with prolonged
prosthetic access primary patency. Randomized studies are needed to confirm the causal role of ARBs and to determine
the optimal therapeutic regimen (dose, timing, and duration) to promote access patency. (J Vasc Surg 2011;54:
1706-12.)
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sHemodialysis access problems are a major cause of
morbidity among patients with end-stage renal disease. In
the United States, access problems account for 20% of
hospitalizations among patients with end-stage renal dis-
ease and more than $1 billion annually in healthcare spend-
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1706ng.1 Access failure is the major cause of access-related
orbidity and occurs with startling frequency, with arterio-
enous (AV) access primary patency at 2 years ranging from
0% to 69% for autogenous access, and from 18% to 30% for
rosthetic access.2,3
Medication use has attracted some attention as a possi-
le protective factor for AV access patency, but published
eports have yielded conflicting and inconclusive re-
ults.4-13 Medications may improve AV access patency by
reventing intimal hyperplasia or thrombosis. The most
rominent study to date was the Dialysis Outcomes and
ractice Patterns Study (DOPPS), which found that
ngiotensin-converting enzyme (ACE) inhibitors were as-
ociated with improved autogenous access secondary pa-
ency, and that calcium channel blockers and aspirin were
ssociated with prolonged prosthetic access primary and
econdary patency, respectively.4 Several other studies also
upported a beneficial effect of ACE inhibitors5-7,12,13 or
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Volume 54, Number 6 Jackson et al 1707antiplatelet agents,8 whereas other studies found no benefit
from antiplatelet therapy.9,10 The majority of studies, how-
ever, have not controlled for use of multiple medications,
opening the possibility of confounding by concomitant
medical therapy. To address this, we undertook a study to
assess the independent association of each of 12medication
classes with AV access primary patency.
METHODS
Patient cohort. We undertook a retrospective cohort
study of upper extremity permanent AV hemodialysis ac-
cesses placed at the Veterans Affairs (VA)Medical Center in
Washington, DC, between January 1, 2005 and December
31, 2009. Procedures were identified using Current Proce-
dure Terminology codes (36818, 36819, 36820, 36821,
36825, and 36830), and operative notes were reviewed to
include all de novo autogenous or prosthetic AV hemodi-
alysis access placements.
Exclusion criteria were placement of a lower extremity
AV access or access failure without recorded date of failure,
because we were studying the association of medication use
with long-term patency. Autogenous accesses with primary
nonfunction, defined as a patent autogenous access with
inadequate venous dilatation for initial hemodialysis access,
were also excluded, because their long-term functional
patency could not be assessed. Electronic medical records
were reviewed to obtain information on outcome, medica-
tion use, and potential confounders for each access. Twelve
medication classes were defined (Table I), and their associ-
ations with access patency were examined.
Preoperative evaluation. At the Washington, DC,
VAMedical Center, arterial sufficiency for AV access place-
ment is assessed preoperatively with a pulse examination. In
patients with a normal pulse examination, further examina-
tions are not undertaken; in patients with an abnormal
pulse examination, segmental pressures and peripheral vas-
Table I. Twelve medication classes
Medication class
Blood pressure medication ACE inhibitors
Angiotensin receptor blockers
Beta blockers
Calcium channel blockers
Diuretics
Other antihypertensive agents
“Blood thinners” Antiplatelet agents
Anticoagulants
Lipid-lowering medication HMG CoA reductase inhibito
Other lipid-lowering agents
Folic acid
Other Antiangina agents
ACE, Angiotensin-converting enzyme; HMG CoA, 3-hydroxy-3-methyl-glucular resistance studies are obtained. Venous adequacy is cefined as venous diameter 2.5 millimeters. In patients
ith clearly visible superficial veins of adequate diameter,
urther studies are not undertaken; otherwise, venous di-
meter is assessed using duplex venous ultrasound scan
xamination. In any patient with a history concerning for
entral venous stenosis, such as previous central line place-
ent, or physical examination findings consistent with
enous hypertension, a preoperative venogram is per-
ormed.
Statistical analysis. The study outcome, primary ac-
ess patency, was defined as freedom from access failure or
ntervention to prevent access failure, according to the
ociety for Vascular Surgery’s Reporting Standards.14
The date of failure (thrombosis, intervention for steno-
is, or abandonment) was recorded for each access. For
ccesses in patients who died or were lost to follow-up, the
ate of the last documented functional patency (censoring)
as recorded.
Patient characteristics, including demographics (age,
ender, race), behaviors (smoking, intravenous drug use),
omorbidities (hypertension, diabetes), and access charac-
eristics (graft material, previous access in the same extrem-
ty, access anatomy), were compared between users and
onusers of each medication class. The 2 statistic was used
o compare binary and categorical variables, and t test was
sed to compare the continuous variable (age). To test for
ulticollinearity, we examined tolerance and variance in-
ation using weighted linear regression. High multicol-
inearity was defined as tolerance 0.4.
Survival analyses were performed within two sub-
roups, defined as autogenous vs prosthetic access. Kaplan-
eier methods were used to calculate unadjusted patency
ates. Cox proportional hazard models with accesses clus-
ered within patients and robust variance were used to
ssess risk of access failure. Each of the medication catego-
ies and the patient characteristics listed above were in-
Medication name
Benazepril, enalapril, fosinopril, lisinopril
Irbesartan, losartan, valsartan
Atenolol, bisoprolol, carvedilol, labetolol,
metoprolol, propranolol
Amlodipine, diltiazem, felodipine, nifedipine,
verapamil
Acetazolamide, furosemide, metolazone,
spironolactone, torsemide
Clonidine, hydralazine, minoxidil
Aspirin, clopidogrel
Enoxaparin, warfarin
statins”) Atorvastatin, fluvastatin, lovastatin, pravastatin,
rosuvastatin, simvastatin
Ezetimibe, fenofibrate, gemfibrozil
Folic acid
Isosorbide dinitrate, isosorbide mononitrate,
nitroglycerin
CoA.rs (“luded as covariates. Any medication class with fewer than
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December 20111708 Jackson et al10 accesses exposed was not included in the model. P
values for each covariate were generated using likelihood
ratio 2 tests. To identify effect modification between med-
ication classes, we expanded the Cox proportional hazard
models to include the interactions between any significant
medication class and all other medication classes. Subgroup
analysis was used to study any significant interaction term.
Stata version 11 (College Station, Tex) was used for all
statistical analyses. A P value of  .05 was defined as
statistically significant.
The Institutional Review Board for the Veterans Affairs
Medical Center in Washington, DC, approved this study.
RESULTS
Two hundred sixty autogenous and 126 prosthetic AV
hemodialysis accesses were identified as eligible for the
study. After exclusions (Fig 1), 212 autogenous accesses
and 120 prosthetic accesses were analyzed for primary
patency.
Primary patency rates at 2 years were 49.1% for auto-
genous accesses and 29.7% for prosthetic accesses (Table
II). Among both autogenous and prosthetic accesses, un-
adjusted patency rates were higher at 2 years among angio-
tensin receptor blockers (ARB) users, compared to nonus-
ers (Table II; Fig 2).
ARB users were more likely to be diabetic, compared to
Fig 1. Subject inclusion/
Table II. Unadjusted 2-year primary patency rates, by
access type (autogenous vs prosthetic) and medication use
Autogenous accesses Prosthetic accesses
Overall 49.1% (41.2%-56.5%) 29.7% (19.0%-41.3%)
ARB users 74.6% (57.7%-85.5%) 62.2% (37.8%-79.4%)
ARB nonusers 41.3% (32.4%-50.1%) 20.0% (9.7%-32.9%)
ARB, Angiotensin receptor blocker.ARB nonusers (75.4% vs 58.8%; P  .014; Table III). lhere was also a nonsignificant trend toward a higher
requency of hypertension among ARB users, compared to
RB nonusers (61.8% vs 49.2%; P  .065). Use of ARBs
as associated with use of antiplatelet medications, beta
lockers, calcium channel blockers, statins, “other” antihy-
ertensives, and “other” lipid-lowering agents (Table IV).
ther baseline characteristics were similar between ARB
sers and nonusers (Tables III, IV, and V).
On multivariable analysis (Table VI), ARBs reduced
he risk of autogenous access failure by 65% (hazard ratio
HR], 0.35; 95% confidence interval [CI], 0.16-0.76; P 
008). There was a statistically significant interaction be-
ween ARBs and antiplatelets on autogenous access primary
atency (P  .022). On subgroup analysis, ARBs pro-
onged autogenous access primary patency by 84% among
atients receiving antiplatelet agents (HR, 0.16; 95% CI,
.05-0.52; P  .002) but had no demonstrable benefit
mong patients not receiving antiplatelet agents (HR, 1.35;
5% CI, 0.34-5.31; P  .670). Access anatomy was not
ignificantly associated with patency, although there was a
rend toward increased risk of access failure for lower arm
ndirect accesses, compared to lower arm direct accesses
OR, 2.28; 95% CI, 0.93-5.61; P  .073). No other
atient or access characteristics were significantly associated
ith autogenous access failure.
On multivariable analysis (Table VII), ARBs reduced
he risk of prosthetic access failure by 59% (HR, 0.41;
5% CI, 0.18-0.95; P  .039). ARBs did not have
ignificant interaction with any other medication class in
he analysis of prosthetic access patency. Diabetes was
ssociated with higher risk of prosthetic access failure
HR, 2.15; 95% CI, 1.04-4.43; P  .039). No other
atient or access characteristics were associated with
rosthetic access patency.
For all variables, tolerances were 0.62 and variance
nflation factors were 1.79, indicating low multicol-
sion. AV, Arteriovenous.inearity, so all variables were retained in the model.
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Volume 54, Number 6 Jackson et al 1709Log-log plots and Schoenfeld residuals indicated there
were no violations of proportional hazards or other
model assumptions.
DISCUSSION
Despite the substantial health and economic burden of
hemodialysis access failure, little is known about interven-
tions to improve primary patency. The only accepted mod-
Fig 2. Autogenous (A) and prosthetic (B) arteriovenou
(ARB) users and nonusers. Shaded areas indicate 95% co
Table III. Baseline characteristics, by ARB use
ARB
(n  69)
No ARB
(n  263) P value
Age (mean) 62.5 62.8 .408
Male, % 100 98.8 .379
Race, % .879
Black 83.1 83.9
Other 16.9 16.1
Smoking status, % .455
Current 36.1 30.8
Former 37.7 46.2
Never 26.3 23.1
IV drug use, % .255
Current/former 10.8 16.5
Never 89.2 83.5
Comorbidities, %
Diabetes 75.4 58.8 .014
Hypertension 61.8 49.2 .065
Graft material, % .827
Autogenous 66.2 64.7
Prosthetic 33.9 35.3
Previous access in
same arm, % 44.6 40.6 .553
ARB, Angiotensin receptor blocker; IV, intravenous.ifiable risk factor for access failure is use of prosthetic graft daterial.2,3,15 Our data suggest that therapy with the com-
ination of ARB plus antiplatelet agent is associated with
mproved autogenous access patency, and that therapy with
RBs alone is associated with improved prosthetic access
atency.
Previous reports of medication effects on AV access
atency are of relatively low quality and have yielded con-
icting results. The effect of antiplatelet medications is the
ost studied, with three small randomized clinical trials
200 patients each) published in the literature. One trial
eported reduced incidence of primary autogenous AV
ccess failure at 8 weeks among patients using clopidogrel
vs placebo),8 whereas another reported protective effect of
) access primary patency, in angiotensin receptor blocker
nce interval (CI).
able IV. Medication use, by ARB use
ARB
(n  69)
No ARB
(n  263) P value
CE inhibitor, % 41.2 40.1 .869
ntiangina agent, % 19.1 12.2 .139
nticoagulant, % 2.9 4.2 .635
ntiplatelet medication, % 70.6 49.2 .002
eta blocker, % 83.8 68.3 .012
alcium channel blocker, % 77.9 63.0 .020
iuretic, % 41.2 29.8 .073
Statin” (HMG CoA
reductase inhibitor), % 61.8 43.5 .007
olic acid, % 7.4 7.3 .977
ntihypertensive, other, % 52.4 28.6 .001
ipid-lowering agent, other, % 8.8 1.9 .005
CE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
MG CoA, 3-hydroxy-3-methyl-glutaryl-CoA.s (AVipyridamole (vs placebo) but detrimental effect of aspirin
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December 20111710 Jackson et al(vs placebo) on prosthetic AV access patency at 18
months.10 Finally, a third trial found no benefit of clopi-
dogrel plus aspirin (vs placebo) on prosthetic AV access
patency, and the trial was halted due to increased frequency
of bleeding episodes in the clopidogrel plus aspirin arm.9 A
retrospective analysis of 2844 AV accesses from theDOPPS
Table V. Access anatomy, by ARB use
ARB
(n  45)
No ARB
(n  167) P value
Autogenous access anatomy, % .661
Lower arm, direct 45.5 54.8
Lower arm, indirect 9.1 7.2
Upper arm, direct 11.4 12.1
Upper arm, indirect 34.1 25.9
ARB
(n  24)
No ARB
(n  96) P value
Prosthetic access anatomy, % .322
Lower arm, loop 66.7 54.2
Lower arm, straight 16.7 13.5
Upper arm, straight 16.7 32.3
ARB, Angiotensin receptor blocker.
Table VI. Adjusted relative hazard of autogenous access
failure
HR (95% CI) P value
Demographics
Increasing age (years) 1.00 (0.98-1.03) .848
Black race 1.84 (0.92-3.68) .085
Smoking status
Current Reference Reference
Former 0.93 (0.46-1.90) .843
Never 0.87 (0.47-1.61) .663
Comorbidities
Diabetes 1.26 (0.74-2.13) .399
Hypertension 0.88 (0.55-1.43) .610
Previous access in same arm 0.84 (0.44-1.62) .602
Access anatomy
Lower arm, direct Reference Reference
Lower arm, indirect 2.28 (0.93-5.61) .073
Upper arm, direct 0.54 (0.21-1.37) .196
Upper arm, indirect 0.88 (0.45-1.75) .724
ARB 0.35 (0.16-0.76) .008
Beta blocker 0.58 (0.30-1.09) .091
Antiplatelet medication 0.77 (0.42-1.43) .405
ACE inhibitor 0.76 (0.47-1.22) .253
Antiangina agent 0.85 (0.42-1.73) .649
Anticoagulant 0.40 (0.11-1.42) .158
Calcium channel blocker 0.81 (0.47-1.37) .426
Diuretic 0.68 (0.41-1.14) .145
Folate 1.04 (0.44-2.46) .921
“Statin” (HMG CoA
reductase inhibitor) 1.38 (0.81-2.35) .236
Antihypertensive, other 1.06 (0.57-1.96) .852
Lipid-lowering agent, other 2.51 (0.75-8.39) .136
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
CI, confidence interval; HMG CoA, 3-hydroxy-3-methyl-glutaryl-CoA;
HR, hazard ratio.longitudinal database reported improved secondary pros- ahetic AV access patency among patients using aspirin, but
id not control for other medication use,4 whereas another
etrospective study of 901 AV accesses from a different
ongitudinal database controlled for use of other medica-
ion classes and reported higher incidence of autogenous
V access failure among patients receiving aspirin.11
We found no randomized studies of renin-angiotensin-
ldosterone system inhibition and AV access patency in the
nglish literature. However, several cohort studies re-
orted an association between use of ARBs, or ACE inhib-
tors and ARBs, considered together, and prolonged pros-
hetic AV access primary patency.5-7 In contrast, the
etrospective analysis in the DOPPS database, mentioned
bove, found no relationship between ARB use and AV
ccess patency.4
ARBs and antiplatelet agents each exhibit pharmaco-
ogic properties that may explain the association with pro-
onged AV access patency demonstrated in our study. ARBs
re primarily used as antihypertensive agents, working
hrough angiotensin II type 1 receptor blockade to prevent
ngiotensin II-mediated vasoconstriction.16 ARBs also play
role in three mechanisms that may prolong access pa-
ency: promoting venous dilation,17,18 preventing platelet
able VII. Adjusted relative hazard of prosthetic access
ailure
HR (95% CI) P value
emographics
Increasing age (years) 0.99 (0.96-1.03) .788
Black race 0.67 (0.24-1.93) .463
moking status
Current Reference Reference
Former 1.19 (0.48-2.93) .709
Never 1.33 (0.55-3.17) .525
omorbidities
Diabetes 2.15 (1.04-4.43) .039
Hypertension 1.53 (0.69-3.41) .293
revious access in same arm 0.96 (0.52-1.77) .888
ccess anatomy
Lower arm, looped Reference Reference
Lower arm, straight 0.56 (0.19-1.68) .299
Upper arm, straight 0.86 (0.45-1.65) .650
ngiotensin receptor
blocker 0.41 (0.18-0.95) .039
eta blocker 1.28 (0.66-2.49) .461
ntiplatelet medication 0.97 (0.54-1.76) .933
CE inhibitor 0.53 (0.24-1.16) .110
ntiangina agent 0.59 (0.17-2.09) .417
nticoagulant N/Aa N/Aa
alcium channel blocker 0.70 (0.40-1.24) .227
iuretic 1.43 (0.61-3.35) .415
olate 0.53 (0.09-3.19) .487
Statin” (HMG CoA
reductase inhibitor) 0.54 (0.25-1.15) .113
ntihypertensive, other 1.11 (0.37-3.30) .858
ipid-lowering agent, other N/Aa N/Aa
CE, Angiotensin-converting enzyme; CI, confidence interval;HMG CoA,
-hydroxy-3-methyl-glutaryl-CoA; HR, hazard ratio; N/A, not applicable.
Excluded from model due to small sample size using medication (antico-
gulant, n  3; lipid-lowering agent, other, n  1).ctivation,19,20 and inhibiting neointimal hyperplasia.21-29
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Volume 54, Number 6 Jackson et al 1711Our data suggest that the association of ARB with autoge-
nous AV access patency is potentiated by use of antiplatelet
medication. Improved autogenous access patency may rely
on the combined effects of ARB-induced venous dilation
and prevention of stenosis and antiplatelet inhibition of
platelet function. Although ARB-antiplatelet interaction
was not detected in prosthetic accesses in our study, this
may be due to the smaller sample size of the prosthetic
access group, compared to the autogenous access group.
One strength of the present study is that the statistical
analysis simultaneously controlled for the use of each of the
12 medication classes, whereas most observational studies
of medications and AV access patency have not controlled
for concurrent medication use. We found that use of ARBs
was highly correlated with use of other medications (Table
V). Previous reports’ failure to control for concurrent med-
ication use may have seriously confounded study results,
andmay explain some of the differences between our results
and those of previous studies. There are, however, some
limitations to our analysis due to its retrospective nature.
Most notably, time using each medication was not consid-
ered in the analysis. This design, however, reflects real-life
experience in which patient compliance affects medication
efficacy. Additionally, the study population was predomi-
nantly male and of African American race, due to the
demographics of the veterans population at our VAmedical
center. It will be important, therefore, to validate these
study findings in other patient populations.
Our study data suggest that, after controlling for pa-
tient characteristics and use of other medications, ARBs
plus antiplatelets are associated with prolonged autogenous
AV access patency, whereas ARBs alone are associated with
prolonged prosthetic AV access patency. Although the
present study cannot prove that ARB administration pro-
longs AV access patency, it does highlight an area of poten-
tial therapeutic benefit warranting further study. Random-
ized clinical trials are needed to evaluate causation, as well
as to determine the optimal therapeutic regimen (dose,
timing, duration) of ARBs to promote access patency.
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